Clinical trial
Fasiglifam 25 mg BID vs 50 mg QD
NCT01982253
Study timeline
Study start (unknown)2013-10-01Date precision: month
Registry last updated2016-10-07
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Type 2 Diabetes Mellitusunresolved
Interventions
FasiglifamDRUG
Sponsors & collaborators
Takedalead sponsor
Mapped research locations
HoustonTexas, United States1ChicagoIllinois, United States1Los AngelesCalifornia, United States1DallasTexas, United States1MiamiFlorida, United States1San AntonioTexas, United States1PortlandOregon, United States1OrlandoFlorida, United States1TaipeiTaiwan1Salt Lake CityUtah, United States1CharlotteNorth Carolina, United States1LexingtonKentucky, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01982253 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.